头豹词条报告系列：中国过敏性疾病行业市场规模测算逻辑模型

Investment Rating - The report does not explicitly state an investment rating for the allergy disease industry in China Core Insights - The market size for allergy diseases in China is projected to grow from CNY 383.82 billion in 2019 to CNY 778.74 billion by 2028, with a compound annual growth rate (CAGR) of approximately 10.17% from 2023 to 2028 [10][11] - The prevalence of allergy diseases is expected to increase from 34% in 2019 to 40.5% by 2028, indicating a growing public health concern [19][21] - The number of patients seeking treatment for allergy diseases is anticipated to rise from approximately 2.38 million in 2019 to about 4.28 million by 2028 [11][30] - The average treatment cost per patient is projected to increase from CNY 1,614.07 in 2019 to CNY 1,817.79 by 2028, reflecting a steady rise in healthcare expenses [12][84] Summary by Sections Market Size - The market size for allergy diseases in China is estimated to grow significantly, reaching CNY 778.74 billion by 2028, with a steady growth rate observed over the years [10][11] Patient Statistics - The number of patients diagnosed with allergy diseases is expected to increase from 2.38 million in 2019 to 4.28 million by 2028, indicating a rising trend in diagnosis and treatment [11][30] - The prevalence rate of allergy diseases is projected to rise from 34% in 2019 to 40.5% by 2028, highlighting an increasing public health issue [19][21] Treatment Costs - The average treatment cost per patient is forecasted to grow from CNY 1,614.07 in 2019 to CNY 1,817.79 by 2028, indicating an upward trend in healthcare spending [12][84] - The breakdown of treatment costs shows that non-antibody drug treatment accounts for approximately 64% of total treatment expenses, while antibody drug treatment comprises about 28% [39][48] Healthcare Access - The consultation rate for allergy diseases is expected to increase from 4.96% in 2019 to 7.5% by 2028, reflecting improved awareness and access to healthcare services [25][26]